Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities.
Saved in:
| Title: | Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities. |
|---|---|
| Authors: | Ge J; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK., Hirosue S; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK., Castillon L; Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Patel SA; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.; Wellcome Sanger Institute, Cambridge, UK., Wesolowski L; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK., Dyas A; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK., Yong C; Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., de Haan S; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan 25, Utrecht, 3584 CS, The Netherlands., Drost J; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan 25, Utrecht, 3584 CS, The Netherlands.; Division of Cell Biology, Metabolism & Cancer, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands., Stewart GD; Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK., Obenauf AC; Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria., Muñoz-Espín D; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK. dm742@cam.ac.uk.; Thoracic Cancer Programme, CRUK Cambridge Centre, Cambridge, UK. dm742@cam.ac.uk., Vanharanta S; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK. sakari.vanharanta@helsinki.fi.; Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. sakari.vanharanta@helsinki.fi.; Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. sakari.vanharanta@helsinki.fi. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2026 Feb; Vol. 18 (2), pp. 599-619. Date of Electronic Publication: 2025 Dec 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1757-4684 |
|---|---|
| DOI: | 10.1038/s44321-025-00361-w |
